Trump to Sign Executive Order Reclassifying Cannabis, Setting Stage for Policy Shift
President Donald Trump is poised to sign an executive order that would reclassify cannabis, a pivotal move that could reshape U.S. drug policy after decades of stringent restrictions. This order is anticipated to elevate cannabis from a Schedule I narcotic to a Schedule III drug, aligning it with medications such as Tylenol with codeine. Despite this change, cannabis will continue to be illegal at the federal level.
Why It Matters
This executive order holds substantial implications for both the cannabis industry and research on its medical benefits. By reclassifying cannabis, the move could foster greater scientific inquiry into its uses and applications. However, the potential policy change also faces strong opposition from some lawmakers who express concerns about the normalization of cannabis use in American society.
Key Developments
- The executive order is expected to be signed as early as Thursday, as indicated by multiple U.S. media reports.
- Reclassifying cannabis to Schedule III would promote research into its therapeutic potential, despite it remaining illegal federally.
- The change could impact tax regulations for state-authorized cannabis dispensaries, allowing them tax deductions not currently accessible due to its Schedule I status.
- A pilot program may be introduced, reimbursing older Americans for cannabidiol (CBD) for conditions like cancer treatment.
- A significant proportion of states, 24, have legalized recreational cannabis, while an even larger number allows medical use.
Full Report
Trump’s Justification
Trump has expressed a desire to amend U.S. cannabis regulation, citing an abundance of research that remains inaccessible due to its current classification. He stated that the reclassification is essential to “end endless arrests and incarcerations of adults for small amounts of marijuana for personal use.” Furthermore, he underscored the need for “smart regulations” to ensure adults have access to safe, tested cannabis products.
Opposing Views from Lawmakers
However, the proposal faces criticism from some Republican legislators who argue that the move could hinder America’s industrial growth and perpetuate health risks. A letter from 22 Republican Senators criticized cannabis normalization, highlighting concerns over its potential impacts on judgment and concentration.
Additionally, a letter from nine Republican representatives expressed skepticism regarding the scientific basis for rescheduling cannabis, arguing that its potential for abuse should preclude any changes to its classification. They contend that reclassification could mislead the public, particularly children, into perceiving cannabis as a safe substance.
Public Opinion
Despite opposition from certain lawmakers, public sentiment appears to lean toward marijuana legalization. A Gallup poll indicated that 64% of Americans support legalizing cannabis, although this number has experienced a slight decline, notably among Republican respondents.
Context & Previous Events
Since 1971, cannabis has been classified as a Schedule I narcotic, which denotes a substance with a high potential for abuse and no accepted medical value. Previous administration efforts, including those from the Biden administration and a DEA proposal in April 2024, aimed to address cannabis classification but faced administrative hurdles.
